---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-012063"
form_type: "8-K"
ticker: null
cik: "0001656536"
company_name: "Decibel Therapeutics, Inc."
filed_at: "2023-04-06T23:59:59+00:00"
generated_at: "2026-06-17T05:11:23.193986+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Decibel Therapeutics amends bylaws to update proxy rules and stockholder meeting procedures

## Summary
- Eliminated requirement to make stockholder list available during the actual meeting.
- Added provisions for adjourning meetings due to technical failure in remote communication.
- Enhanced disclosure requirements for stockholder nominations and proposals under universal proxy rules.
- Requires evidence of compliance with Rule 14a-19 solicitation requirements at least 5 business days before meeting.
- Non-compliant nominations will be disregarded; proxies for such nominees not counted.

## SEC filing metadata
- accession: 0000950170-23-012063
- form_type: 8-K
- cik: 0001656536
- company_name: Decibel Therapeutics, Inc.
- filed_at: 2023-04-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1656536/000095017023012063/0000950170-23-012063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1656536/000095017023012063/dbtx-20230404.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-012063
- JSON: https://secwatch.observer/filing/0000950170-23-012063.json
- Plain text: https://secwatch.observer/filing/0000950170-23-012063.txt

## Key facts
- Governance Changes
  Decibel Therapeutics, Inc.: Amended and restated bylaws effective immediately, including changes to stockholder meeting procedures, universal proxy rules, and other updates (effective 2023-04-04).
  - Change: bylaw amendment
  - Effective: 2023-04-04
  source text: On April 4, 2023, the board of directors (the “Board”) of Decibel Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1656536/000095017023012063/0000950170-23-012063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.